Charles River Laboratories International (NYSE:CRL) Raised to Neutral at Citigroup
Charles River Laboratories International (NYSE:CRL – Get Free Report) was upgraded by equities research analysts at Citigroup from a “sell” rating to a “neutral” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $175.00 price objective on the medical research company’s stock, up from their prior price […]
Charles River Laboratories International (NYSE:CRL – Get Free Report) was upgraded by equities research analysts at Citigroup from a “sell” rating to a “neutral” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $175.00 price objective on the medical research company’s stock, up from their prior price […]
